Stock prices for embryonic stem cell research companies took a hit when the U.S. Senate failed to pass a bill to overturn President Bush’s stem cell funding policy by a veto proof margin. Worcester, MA’s, Advanced Cell Technology—which opened an office in California to try and take advantage of the cornicopia of Proposition 71 money—lost value, as did California’s Geron. Some adult stem cell companies also lost ground, but others gained.
Well, the market doesn’t lie: A big part of the drive to overturn Bush’s policy is pure corporate welfare pork. Sooweeee!
YOU MIGHT ALSO LIKE
Moral Certitude and the Iran War
The current military engagement with Iran calls renewed attention to just war theory in the Catholic tradition.…
The Slow Death of England: New and Notable Books
The fate of England is much in the news as popular resistance to mass immigration grows, limits…
Ethics of Rhetoric in Times of War
What we say matters. And the way we say it matters. This is especially true in times…
